Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus

  • Diabetes and Cardiovascular Disease (S Malik, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Over the past several years, there have been a significant number of new agents developed for the treatment of type 2 diabetes. Our goal in this article is to review the cardiovascular effects (risks and benefits) of these oral and non-insulin injectable agents. We review six major categories of diabetic therapies: biguanides, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, GLP-1 agonists, and DPP-IV inhibitors. In order to achieve a personalized regimen that aims for optimal outcomes, we must take into consideration each drug’s side effects, patients’ cardiovascular risk factors, and their individual health profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. National Diabetes Fact Sheet, 2011. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed 2011.

  2. Hemmignsen B, Lund SS, Wetterslev J, Vaag A. Oral hypoglycemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol. 2009;161:1–9.

    Article  Google Scholar 

  3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.

    Article  Google Scholar 

  4. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

    Article  Google Scholar 

  5. • Messaoudi SE, Rongen GA, de Boer RA, Riksen NP. The cardioprotective effects of metformin. Curr Opin Lipidol. 2011;22:445–53. This is a recent review of myocardial ischemia-reperfusion injury and metformin in animal models.

    Article  PubMed  Google Scholar 

  6. Palumbo PJ. Metformin: effects on cardiovascular risk factors in patients with non insulin-dependent diabetes mellitus. J Diabetes Complicat. 2008;12:110–9.

    Article  Google Scholar 

  7. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Int Med. 2008;168:2070–80.

    Article  Google Scholar 

  8. •• Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616–25. This is one of the few randomized controlled trials, as a follow up to the UKPDS, that showed an improvement in macrovascular outcomes when metformin was added to an insulin regimen.

    Article  PubMed  CAS  Google Scholar 

  9. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900–8.

    Article  PubMed  CAS  Google Scholar 

  10. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892–9.

    Article  PubMed  CAS  Google Scholar 

  11. McAlister FA, Eurich DT, Majumdar SR, Johnson JA, et al. The risk of heart failure in patients with type 2 diabetes treated with oral agent Monotherapy. Eur J Heart Fail. 2008;10:703–8.

    Article  PubMed  CAS  Google Scholar 

  12. Eurich DT, McAlister FA, Balckburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Available at bmj.com. Accessed 2007.

  13. Sadikot S, Mogensen CE. Risk of coronary artery disease associated with initial sulfonylurea treatment of patients with type 2 diabetes: a matched case–control study. Diabetes Res Clin Pr. 2008;82:391–5.

    Article  CAS  Google Scholar 

  14. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. JACC. 1998;31:950–6.

    Article  PubMed  CAS  Google Scholar 

  15. Evans JMM, Ogston SA, Reimann F, et al. No differences in mortality between users on pancreatic-specific and non-pancreatic specific sulfonylureas: a cohort analysis. Diabetes Obes Metab. 2008;10:350–2.

    Article  PubMed  Google Scholar 

  16. Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimeperide monotherapy. Diabetes Care. 2010;33:1224–9.

    Article  PubMed  CAS  Google Scholar 

  17. Andersson C, Gislason GH, Jorgensen JH, et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pr. 2011;94:119–25.

    Article  CAS  Google Scholar 

  18. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K + channel blocker. Circulation. 1994;90:700–5.

    Article  PubMed  CAS  Google Scholar 

  19. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning: a double-blind placebo controlled evaluation of glimeperide and glibenclamide. Eur Heart J. 1999;20:439–46.

    Article  PubMed  CAS  Google Scholar 

  20. Zeller M, Danchin M, Simon D, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010;95:4993–5002.

    Article  PubMed  CAS  Google Scholar 

  21. UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 2008;352:853–7.

    Google Scholar 

  22. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. Diabetes Care. 2007;30:389–94.

    Article  PubMed  Google Scholar 

  23. • Pantalone KM, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimeperide monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012;14:803–9. A recent large retrospective review that showed an increased mortality with 3 different sulfonylureas compared to metformin.

    Article  PubMed  CAS  Google Scholar 

  24. Evans JMM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49:930–6.

    Article  PubMed  CAS  Google Scholar 

  25. Vameq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 1999;354:141–8.

    Article  Google Scholar 

  26. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, and glyburide monotherapy. N Engl J Med. 2006;355:2427–43.

    Article  PubMed  CAS  Google Scholar 

  27. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2006;29:1963–72.

    Article  PubMed  Google Scholar 

  28. Nesto RW, Bell D. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American heart association and American diabetes association. Circulation. 2003;108:2941–8.

    Article  PubMed  Google Scholar 

  29. Haffner SM. Epidemiology of hypertension and insulin resistance syndrome. J Hypertens Suppl. 1997;15:S25–30.

    PubMed  CAS  Google Scholar 

  30. Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens. 2006;8:19–28.

    Article  CAS  Google Scholar 

  31. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002;51:797–802.

    Article  PubMed  CAS  Google Scholar 

  32. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–54.

    Article  PubMed  CAS  Google Scholar 

  33. Robinson JG. Should we use PPAR agonists to reduce cardiovascular risk? PPAR Res. Article ID. 2008;891425:1–13.

    Google Scholar 

  34. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366:1279–89.

    Article  PubMed  CAS  Google Scholar 

  35. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561–73.

    Article  PubMed  CAS  Google Scholar 

  36. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.

    Article  PubMed  CAS  Google Scholar 

  37. Medication Guide Avandia. Available at http://www.fda.gov/downloads/Drugs/DrugSafety/ucm085922.pdf. Accessed 2011.

  38. • Standl E, Schnell O, Alpha-glucosidase inhibitors. Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation. Diabetes Vasc Dis Res. 2012;0:1–7. A recent review of studies done on the cardiovascular effects of acarbose.

    Google Scholar 

  39. Van de Laar FA, Lucassen PL, Akkerma RP, et al. Alpha-glycosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28:154–63.

    Article  PubMed  Google Scholar 

  40. • Lin SD, Wang JS, Hsu SR, et al. The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonyurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complicat. 2011;25:332–8. A randomized study that showed the addition of acarbose to metformin causes much lower glucose variability throughout the day compared to the addition of a sulfonylurea, glimeperide.

    Article  PubMed  Google Scholar 

  41. Suzuki Y, Sano M, Hayashida K, et al. Are the effects of a-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract? FEBS Lett. 2009;583:2157–215.

    Article  PubMed  CAS  Google Scholar 

  42. Kajiyama S, Hasegawa G, Asano M, et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr Res. 2008;28:137–43.

    Article  PubMed  CAS  Google Scholar 

  43. Chiasson J, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.

    Article  PubMed  CAS  Google Scholar 

  44. Chiasson J, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–94.

    Article  PubMed  CAS  Google Scholar 

  45. Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35:1073–8.

    Article  PubMed  CAS  Google Scholar 

  46. Hanefeld M, Cagatay M, Petrowitsch T. Acarbose reduces the risk of myocardial infarction in type 2 diabetics: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.

    Article  PubMed  CAS  Google Scholar 

  47. Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest. 2002;22:695–701.

    Article  CAS  Google Scholar 

  48. Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1345–50.

    Article  PubMed  CAS  Google Scholar 

  49. Schisano B, Tripathi G, McGee K, et al. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia. 2011;54:1219–26.

    Article  PubMed  CAS  Google Scholar 

  50. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care. 1991;14:732–7.

    Article  PubMed  CAS  Google Scholar 

  51. Satoh N, Shimatsu A, Yamada K, et al. An a-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism. 2006;55:786–7.

    Article  PubMed  CAS  Google Scholar 

  52. Yokoyama H, Kannno S, Ishimura I, et al. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. Metabolism. 2007;56:1458–63.

    Article  PubMed  CAS  Google Scholar 

  53. Kim W, Egan J. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470–512.

    Article  PubMed  CAS  Google Scholar 

  54. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008;93:3703–16.

    Article  PubMed  CAS  Google Scholar 

  55. Ahren B, Landin-Olsson M, Jansson P, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078–84.

    Article  PubMed  CAS  Google Scholar 

  56. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.

    Article  PubMed  CAS  Google Scholar 

  57. •• Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85. Important article demonstrating how significantly different diabetes outcomes are in patients who undergo bariatric surgery versus medical treatment of diabetes. This could potentially change the stringent requirements patients have to meet in order to qualify for bariatric surgery.

    Article  PubMed  CAS  Google Scholar 

  58. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33:1759–63.

    Article  PubMed  CAS  Google Scholar 

  59. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275–86.

    PubMed  CAS  Google Scholar 

  60. • Addison D, Aguilar D. Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. Curr Atheroscler Rep. 2011;13:115–22. Review article describing benefits of incretin therapies in treatment of cardiovascular disease.

    Article  PubMed  CAS  Google Scholar 

  61. Forst T, Weber MM, Pfutzner A. Cardiovascular benefits of GLP-1 based therapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res. 2012;2012:1–9.

  62. Courreges JP, Vilsbollt T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabetic Med. 2008;25:1129–31.

    Article  PubMed  Google Scholar 

  63. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist Exenatide twice daily or other glucose-lowering therapies. A retrospective analysis of the LifeLink database. Diabetes Care. 2011;34:90–5.

    Article  PubMed  CAS  Google Scholar 

  64. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122:16–27.

    Article  PubMed  Google Scholar 

  65. Bethel MA, Green J, Califf RM, Holman RR. Rationale and design of the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes. 2009;58:A639.

    Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Center for Diabetes Research and Treatment and Departments of Medicine, Biological Chemistry, Physiology and Biophysics, University of California, 845 Health Sciences Road, Gross Hall Rm 2031, Irvine, CA, 92697, USA

    Samar Singh, Jyoti Bhat & Ping H. Wang

Authors
  1. Samar Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jyoti Bhat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping H. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ping H. Wang.

Additional information

This article is part of the Topical Collection on Diabetes and Cardiovascular Disease

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, S., Bhat, J. & Wang, P.H. Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus. Curr Cardiol Rep 15, 327 (2013). https://doi.org/10.1007/s11886-012-0327-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-012-0327-1

Keywords

Search

Navigation